Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Home
/
update
/
details

Thermo Fisher Scientific Finalizes $3.1 Billion Acquisition of Olink

NextEdge Admin

11 Jul 2024

1 min 46 sec

Thermo Fisher Scientific has finalized its acquisition of Olink for $3.1 billion, a deal initially announced in October 2023 but delayed due to regulatory reviews. Thermo Fisher purchased approximately 37,676,600 Olink shares at $26 per share in cash. This acquisition integrates Olink's Explore HT platform, known for its capability to measure over 5,300 proteins in plasma, with Thermo Fisher's mass spectrometry-based proteomics portfolio.

The Explore HT platform enhances Thermo Fisher's capacity in large-scale plasma proteomics research, crucial for advancing insights into human biology and precision medicine. Thermo Fisher's Chairman, President, and CEO, Marc Casper, emphasized the strategic fit of Olink's technologies with their existing offerings in life sciences. Casper highlighted the transformative potential of Olink's solutions in proteomics, underscoring their complementarity with Thermo Fisher's leadership in mass spectrometry.

The acquisition underscores Thermo Fisher's commitment to expanding its capabilities in protein research, aiming to accelerate innovations in biomedical research and therapeutic development. With Olink now integrated into Thermo Fisher, the combined entity is poised to deliver enhanced solutions and drive further advancements in the field of precision medicine.